November 1, 2018 Bio/Pharma/CRO PR/Corporate

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities

Basel, 01 November 2018 Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil Data will be submitted to health authorities and presented... Read more

October 4, 2018 Bio/Pharma/CRO Lab Top-10

MilliporeSigma Opens M Lab™ Collaboration Center in São Paulo, Brazil

News Release October 4, 2018 Your Contact: Karen Tiano +1 978 495 0093 New collaboration center to provide support from pre-clinical through full-scale production in a non-GMP environment Hands-on customer access to MilliporeSigma’s product portfolio, technical expertise Burlington, Massachusetts, October 4, 2018 — MilliporeSigma today officially opened a state-of-the-art M Lab™ Collaboration Center in Brazil, serving the Latin... Read more

October 4, 2018 Bio/Pharma/CRO PR/Corporate

Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018

Basel, 04 October 2018 Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 Baloxavir marboxil – a first-in-class, single-dose, investigational oral medicine – is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable... Read more

October 3, 2018 Bio/Pharma/CRO M&A, Partnerships

University College London in Strategic Alliance with Pall Biotech to Open Fit-for-Purpose Biotech Centre of Excellence for Research, Development and Training

PORT WASHINGTON, N.Y., Oct. 3, 2018 /PRNewswire/ — Pall Corporation, a global leader in filtration, separation and purification, has progressed a strategic partnership with the University College London (UCL) Biochemical Engineering department with the creation of the UCL-Pall Biotech Centre of Excellence (CoE) for research and training. The UCL-Pall Biotech CoE will be operational from September 2018 through 2024 with a management committee... Read more

October 2, 2018 Bio/Pharma/CRO Environ, Ag./Food & Bev Industrial

DNA Script Announces World’s First Enzymatic Synthesis of a High-Purity 150-Nucleotide Strand of DNA

DNA Script’s approach achieves parity with conventional chemical synthesis — and is poised to quickly surpass the current gold standard in speed, efficacy and length for commercial DNA synthesis. October 02, 2018 01:40 PM Pacific Daylight Time SAN FRANCISCO, Calif.–(BUSINESS WIRE)–DNA Script, the global leader in the development of enzymatic DNA synthesis, today announced that... Read more

September 27, 2018 Bio/Pharma/CRO Lab Top-10

Thermo Fisher Scientific Cryo-EM Instruments Help Pharmaceutical Consortium Advance Drug Discovery and Development

Thermo Fisher Scientific Cryo-EM Instruments Help Pharmaceutical Consortium Advance Drug Discovery and Development HILLSBORO, Ore., Sept. 27, 2018 /PRNewswire/ — Only two years after its formation, the Cambridge Pharmaceutical Cryo-EM Consortium is increasing capacity of Thermo Scientific cryo-EM instruments. Researchers from member companies use Thermo Scientific Krios G3i Cryo Transmission Electron Microscope (Cryo-TEM) instruments to... Read more

September 26, 2018 Bio/Pharma/CRO Cell Analysis Tools M&A, Partnerships

Nanion Technologies places two SyncroPatch 384PE Instruments for Ion Channel Screening at Charles River Laboratories

https://www.nanion.de/images/Downloads_pdf/Press_Releases/180926_PR_Charles_River.pdf   Livingston, N.J., Munich, Germany, September 26, 2018: Nanion announced today that Charles River Laboratories has purchased two SyncroPatch 384PE high-throughput patch clamp instruments. This purchase reflects an investment in screening technologies and assay development, while accommodating the rising demand in contract service for globally shared clients. The instruments will be delivered to Charles... Read more

September 26, 2018 Bio/Pharma/CRO M&A, Partnerships

Reaction Biology and Promega Launch New Cell Assay Service

Malvern PA – September 24, 2018. A new cell based profiling service for drug discovery announced by Reaction Biology Corporation (RBC), a premier provider of drug discovery services, and Promega Corporation, a worldwide leader in the supply of life science products, will allow more researchers to better prioritize compounds earlier. Based on Promega NanoBRETTM technology,... Read more

September 24, 2018 Bio/Pharma/CRO

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid

Basel, 24 September 2018 Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic testing and so may benefit from FoundationOne Liquid FoundationOne Liquid... Read more